"small cell carcinoma" Veja tudo que foi noticiado aqui

New trials show promise for immune checkpoint blockers in early-stage lung cancer

A dendritic cell (DC) vaccine targeting patient-specific neoantigens to patients with resected non-small cell lung cancer (NSCLC).
Fonte: News Medical on MSN

Treatment Options For Hurthle Cell Cancer

Hurthle cell cancer is a type of malignant tumor that affects the thyroid, the butterfly-shaped gland in the neck.
Fonte: HealthPrep on MSN

FDA approves Roche's Alecensa for early stage ALK+ lung cancer

Alecensa for the treatment of early stage resected non-small stage lung cancer with ALK+ mutations. Read more here.
Fonte: Seeking Alpha on MSN

Potential therapeutic target for small cell lung cancer discovered

Northwestern Medicine investigators have discovered that inhibiting a chromatin remodeling complex associated with a particular gene in small-cell lung cancer (SCLC) cells may decrease cancer cell ...
Fonte: Medical Xpress on MSN

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung ...
Fonte: YAHOO!Finance

NIH team develops AI tool to predict cancer drug response

Researchers at the National Cancer Institute, a unit of the National Institutes of Health (NIH) in the US, have developed an AI tool that can predict drug responses in cancer treatment.
Fonte: Pharmaceutical Technology

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment ...
Fonte: YAHOO!Finance

Combination therapy can delay resistance of lung cancer cells

A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These ...
Fonte: Medical Xpress on MSN

Researchers search for new lung cancer drug

MORGANTOWN — Science is a team sport, and a group of West Virginia University researchers with differing expertise and approaches are joining forces to seek a drug for non-small cell lung cancer ...
Fonte: The Inter-Mountain

Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment

The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 ...
Fonte: The American Journal of Managed Care

AI tool predicts responses to cancer therapy using information from each cell of the tumor

With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting. Most of the focus has been on developing genetic ...
Fonte: Medical Xpress

Visual Proteomics: Observing Protein Location in Living Cells

Proteins function dynamically in cells, and tracking their location precisely in living cells has been a major technical challenge. Current methods involve individually labeling individual proteins ...
Fonte: GEN